PRGO · XBRL financial data

Perrigo Company financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PRGO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	5,063	4,139	4,452	4,656	4,373	4,253
Cost of goods and services sold	3,248	2,723	2,996	2,975	2,831	2,759
Gross profit	1,815	1,416	1,455	1,680	1,543	1,495
Research and development	178	122	123	123	112	95
General and administrative	496	482	512	522	468	436
Total operating expenses	1,700	1,006	1,377	1,529	1,430	2,617
Other operating income (expense)	—	—	(1)	1	(6)	(31)
Operating income (loss)	115	410	79	152	113	(1,122)
Other income (expense)	(17)	(27)	(53)	10	1	(13)
Income tax expense (benefit)	13	390	(8)	(4)	80	104
Net income (loss)	(163)	(69)	(141)	(13)	(172)	(1,425)
Earnings per share, basic USD per share	(1.19)	(0.52)	(1.04)	(0.09)	(1.25)	(10.29)
Earnings per share, diluted USD per share	(1.19)	(0.52)	(1.04)	(0.09)	(1.25)	(10.29)
Weighted average shares, basic millions of shares	136	134	135	135	137	139
Weighted average shares, diluted millions of shares	136	134	135	135	137	139

Fiscal years (PRGO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	642	1,865	601	751	559	532
Accounts receivable	1,054	653	697	740	642	613
Inventory	1,200	1,020	1,150	1,141	1,082	1,149
Prepaid and other current assets	238	306	272	201	199	231
Total current assets	3,134	3,860	2,720	2,833	2,482	2,797
Property and equipment, net	996	864	926	916	918	899
Right-of-use asset	186	167	217	184	175	168
Goodwill	3,769	2,999	3,490	3,529	3,320	2,050
Total assets	11,488	10,426	11,017	10,809	9,648	8,535
Accounts payable	544	411	537	478	495	475
Accrued liabilities	250	279	250	335	239	—
Current portion of long-term debt	38	604	36	441	36	37
Total current liabilities	1,382	1,588	1,114	1,586	1,044	1,013
Long-term debt	3,528	2,917	4,070	3,633	3,582	3,604
Lease liability, non-current	133	147	190	160	154	152
Total liabilities	5,833	5,274	6,175	6,041	5,328	5,600
Accumulated deficit	(1,858)	(1,927)	(2,068)	(2,080)	(2,252)	(3,678)
Total stockholders' equity	5,655	5,152	4,842	4,768	4,319	2,936
Total liabilities and equity	11,488	10,426	11,017	10,809	9,648	8,535
Common shares outstanding (cover page) millions of shares	133	134	135	136	136	138

Fiscal years (PRGO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(163)	(69)	(141)	(13)	(172)	(1,425)
Stock-based compensation	59	60	55	69	64	55
Depreciation and amortization	385	312	339	360	326	338
Net cash from operating activities	636	156	307	406	363	239
Purchases of property and equipment	170	152	96	102	118	93
Net cash from investing activities	(188)	1,276	(1,959)	(78)	79	(75)
Proceeds from issuing common stock	0	0	—	—	—	—
Share repurchases	164	0	0	—	—	—
Dividends paid	124	130	142	150	153	159
Proceeds from long-term debt	744	0	1,587	295	1,091	0
Repayments of long-term debt	590	0	959	325	1,529	35
Net cash from financing activities	(181)	(179)	422	(187)	(611)	(221)
Net change in cash	287	1,238	(1,279)	151	(193)	(25)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
PERRIGO	400	1,023	83*	138.8M	—	Q2 FY26 10-QJun 27, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Ultragenyx Pharmaceutical	125	214	(97)*	98.6M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Avidity Biosciences	383	0.9*	(170)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.